Sigilon Therapeutics’ $144.9 Million Initial Public Offering

Latham & Watkins LLP represented the underwriters in the offering.

Sigilon Therapeutics, Inc. (Nasdaq: SGTX) has announced its upsized initial public offering of 7,000,000 shares of its common stock at an initial public offering price of US$18.00 per share. All of the shares are offered by Sigilon. The aggregate gross proceeds to Sigilon from the offering were $144.9 million, before deducting underwriting discounts and commissions and other offering expenses. Sigilon’s common stock began trading on the Nasdaq Global Market on December 4, 2020 under the symbol “SGTX.”

Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as joint book-running managers for the offering.

Sigilon Therapeutics, Inc. is a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform.

Latham & Watkins LLP represented the underwriters in the offering with a life sciences capital markets team led by partners Peter Handrinos (Picture) and Wesley Holmes, with associates Adam Johnson, Emily Henderson and Laura Harper.

Involved fees earner: Laura Harper – Irwin Mitchell; Peter Handrinos – Latham & Watkins; Emily Henderson – Latham & Watkins; Wesley Holmes – Latham & Watkins; Adam Johnson – Latham & Watkins;

Law Firms: Irwin Mitchell; Latham & Watkins;

Clients: Barclays Bank; Canaccord Genuity; Jefferies; Morgan Stanley;

Print Friendly, PDF & Email

Author: Ambrogio Visconti